Reduction of arginine-vasopressin in the cerebral cortex in Alzheimer type senile dementia
- PMID: 3625218
- PMCID: PMC1032137
- DOI: 10.1136/jnnp.50.7.929
Reduction of arginine-vasopressin in the cerebral cortex in Alzheimer type senile dementia
Abstract
Arginine-vasopressin (AVP) concentrations in five cortical areas were measured post mortem in nine patients with senile dementia of Alzheimer's type (SDAT), and compared with the control group of comparable ages. In SDAT patients, AVP was significantly reduced in Brodmann areas 4, 7 and 10 (p less than 0.05). In areas 17 and 22, the detectability and the mean concentrations of AVP were also lower than those of control patients, although not significantly.
Similar articles
-
Neocortical concentrations of neuropeptides in senile dementia of the Alzheimer and Lewy body type: comparison with Parkinson's disease and severity correlations.Biol Psychiatry. 1991 Feb 15;29(4):357-64. doi: 10.1016/0006-3223(91)90221-7. Biol Psychiatry. 1991. PMID: 1674664
-
Neurotransmitters in dementia.Clin Ther. 1984;7 Spec No:18-34. Clin Ther. 1984. PMID: 6152197
-
Differential alterations of cortical glutamatergic binding sites in senile dementia of the Alzheimer type.Proc Natl Acad Sci U S A. 1990 Feb;87(4):1352-6. doi: 10.1073/pnas.87.4.1352. Proc Natl Acad Sci U S A. 1990. PMID: 2154742 Free PMC article.
-
Senile dementia and presenile dementia.Tohoku J Exp Med. 1990 Aug;161 Suppl:49-60. doi: 10.1620/tjem.161.supplement_49. Tohoku J Exp Med. 1990. PMID: 1707190 Review.
-
[A comparative study on histopathological findings between Alzheimer's disease and senile dementia of Alzheimer type].Rinsho Byori. 1996 Mar;44(3):225-30. Rinsho Byori. 1996. PMID: 8857164 Review. Japanese.
Cited by
-
Vitamin D interacts with Esr1 and Igf1 to regulate molecular pathways relevant to Alzheimer's disease.Mol Neurodegener. 2016 Mar 1;11:22. doi: 10.1186/s13024-016-0087-2. Mol Neurodegener. 2016. PMID: 26932723 Free PMC article.
-
Pharmacodynamic and pharmacokinetic profile of S 17092, a new orally active prolyl endopeptidase inhibitor, in elderly healthy volunteers. A phase I study.Br J Clin Pharmacol. 2000 Oct;50(4):350-9. doi: 10.1046/j.1365-2125.2000.00270.x. Br J Clin Pharmacol. 2000. PMID: 11012558 Free PMC article. Clinical Trial.
-
Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on neuropeptide metabolism in the rat brain.Naunyn Schmiedebergs Arch Pharmacol. 1996 Feb;353(3):355-62. doi: 10.1007/BF00168640. Naunyn Schmiedebergs Arch Pharmacol. 1996. PMID: 8692293
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous